+1 (202) 780-3397
Commentary - Immunology Case Reports (2022) Volume 5, Issue 2
Patient with pulmonary alveolar proteinosis, GM-CSF antibody reduction.
We share our experience of a patient with pneumonic alveolar proteinosis who was recalcitrant to plasmapheresis and rituximab in spite of a critical decrease in the culpable neutralizer. He gave windedness, fevers, chills, and sweats for a considerable length of time. He was determined to have immune system PAP in view of run of the mill radiology discoveries, broncho alveolar liquid examination, and raised enemy of GM-CSF levels. Given his restricted improvement with entire lung lavage and breathed in GM-CSF treatment, he went through two series of plasmapheresis. Series one was 5 methods in 6 days, and series two was 5 strategies in 9 days followed by rituximab. These didn't seem to give any enduring clinical advantage in the year after plasmapheresis regardless of an undeniable decline in serum hostile to GM-CSF levels. In any case, about a year after plasmapheresis, he went into abatement and has not needed any treatment.
Author(s): Aysenur Barksdal